Taiwan Meiji Pharma Launches REZUROCK® Tablets in Taiwan, a selective ROCK2 Inhibitor Indicated for the Treatment of cGVHD

Meiji Holdings Co. Ltd. published this content on March 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 05, 2026 at 01:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]